Gary B. Gordon M.D., Ph.D.
Net Worth
Last updated:
What is Gary B. Gordon M.D., Ph.D. net worth?
The estimated net worth of Dr. Gary B. Gordon M.D., Ph.D. is at least $2,216,720 as of 24 Feb 2021. He has earned $15,480 from insider trading and has received compensation worth at least $2,201,240 in Ayala Pharmaceuticals, Inc..
What is the salary of Gary B. Gordon M.D., Ph.D.?
Dr. Gary B. Gordon M.D., Ph.D. salary is $550,310 per year as Chief Medical Officer in Ayala Pharmaceuticals, Inc..
How old is Gary B. Gordon M.D., Ph.D.?
Dr. Gary B. Gordon M.D., Ph.D. is 72 years old, born in 1953.
What stocks does Gary B. Gordon M.D., Ph.D. currently own?
As insider, Dr. Gary B. Gordon M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ayala Pharmaceuticals, Inc. (AYLA) | Chief Medical Officer | 8,520 | $0 | $0 |
What does Ayala Pharmaceuticals, Inc. do?
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Gary B. Gordon M.D., Ph.D. insider trading
Ayala Pharmaceuticals, Inc.
Dr. Gary B. Gordon M.D., Ph.D. has made 2 insider trades in 2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 3,000 units of AYLA stock on 20 Jan 2021. As of 24 Feb 2021 he still owns at least 8,520 units of AYLA stock.
Ayala Pharmaceuticals key executives
Ayala Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Gary B. Gordon M.D., Ph.D. (72) Chief Medical Officer
- Dr. Roni Mamluk Ph.D. (58) Pres, Chief Executive Officer & Director
- Mr. Yossi Maimon CPA, M.B.A., CPA, MBA (54) Chief Financial Officer, Sec. & Treasurer